Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (81-90 of 282) with videos related to

Pageof 29
Sort By:
British Journal of Clinical Pharmacology|May 9, 2020
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactionsDavid Back, Catia Marzolini, Catherine Hodge, et al.
Clinical Pharmacokinetics|March 13, 2013
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approachMarco Siccardi, Catia Marzolini, Kay Seden, et al.
The Lancet. Neurology|October 16, 2014
Controversies in HIV-associated neurocognitive disordersSam Nightingale, Alan Winston, Scott Letendre, et al.
AIDS (London, England)|July 2, 2014
Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicityJean C Yombi, Anton Pozniak, Marta Boffito, et al.
Antimicrobial Agents and Chemotherapy|February 10, 2016
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal DiseaseJosé Moltó, Fredzzia Graterol, Cristina Miranda, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2012
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategiesAlessandro Schipani, Laura Dickinson, Marta Boffito, et al.
Hepatology (Baltimore, Md.)|December 9, 2014
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virusNikolien van de Ven, Joe Fortunak, Bryony Simmons, et al.
Clinical Pharmacokinetics|March 29, 2023
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro DataSandra Grañana-Castillo, Angharad Williams, Thao Pham, et al.
Neurology. Clinical Practice|March 20, 2020
The neurologic phenotype of South African patients with HIV-associated neurocognitive impairmentSean G Anderson, Michael McCaul, Saye Khoo, et al.
Pharmacogenomics|February 16, 2019
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokineticsJoshua Gini, Adeniyi Olagunju, Laura Dickinson, et al.
Pageof 29

Showing results (81-90 of 282) with videos related to

Sort By:
Pageof 29
British Journal of Clinical Pharmacology|May 9, 2020
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactionsDavid Back, Catia Marzolini, Catherine Hodge, et al.
Clinical Pharmacokinetics|March 13, 2013
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approachMarco Siccardi, Catia Marzolini, Kay Seden, et al.
The Lancet. Neurology|October 16, 2014
Controversies in HIV-associated neurocognitive disordersSam Nightingale, Alan Winston, Scott Letendre, et al.
AIDS (London, England)|July 2, 2014
Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicityJean C Yombi, Anton Pozniak, Marta Boffito, et al.
Antimicrobial Agents and Chemotherapy|February 10, 2016
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal DiseaseJosé Moltó, Fredzzia Graterol, Cristina Miranda, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2012
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategiesAlessandro Schipani, Laura Dickinson, Marta Boffito, et al.
Hepatology (Baltimore, Md.)|December 9, 2014
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virusNikolien van de Ven, Joe Fortunak, Bryony Simmons, et al.
Clinical Pharmacokinetics|March 29, 2023
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro DataSandra Grañana-Castillo, Angharad Williams, Thao Pham, et al.
Neurology. Clinical Practice|March 20, 2020
The neurologic phenotype of South African patients with HIV-associated neurocognitive impairmentSean G Anderson, Michael McCaul, Saye Khoo, et al.
Pharmacogenomics|February 16, 2019
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokineticsJoshua Gini, Adeniyi Olagunju, Laura Dickinson, et al.
Pageof 29